What MK-677 trial results do—and do not—show about lean mass, water weight and strength, with limits for interpreting physique claims.
MK-677 can raise fat-free mass in human studies, but that does not establish how much contractile muscle a younger lifter would gain. FDA's review distinguishes changes in growth hormone, IGF-1 and body composition from a demonstrated improvement in physical function. Those are different outcomes, and a result for one cannot substitute for another. FDA evidence review
Nass and colleagues studied healthy adults aged 60–81. The principal comparison was at one year; 65 participants completed that year. Participants were asked to maintain their usual diet and exercise rather than start a bodybuilding program.
| Average one-year change | MK-677 | Placebo |
|---|---|---|
| Body weight | +2.7 kg | +0.8 kg |
| Fat-free mass by DXA (dual-energy X-ray absorptiometry) | +1.1 kg | −0.5 kg |
| Total body water | +1.7 kg | +0.1 kg |
Compared with placebo, MK-677 did not significantly improve strength or physical function. The small study was not sufficient to settle functional benefits. The second year used a modified crossover: some participants changed treatment. It was not two uninterrupted years of the original comparison. Full trial
The trial does not support that simple conclusion. Extracellular water rose similarly in both groups; intracellular water differed. The authors interpreted the intracellular change as reflecting body cell mass. Water and fat-free mass overlap, so subtracting the water figure from the lean-mass figure does not calculate newly grown muscle. Trial body-water analysis
For a claim about “muscle gains,” first identify the measurement:
The useful response to a progress claim is to ask for the measurement, the comparison group and the time interval. Calling every lean-mass change muscle growth overstates the evidence; dismissing every change as meaningless fluid also goes beyond what was measured. Our body-composition tracking guide explains how to keep these outcomes separate.
FDA's 2024 evaluation found insufficient evidence to establish ibutamoren's effectiveness for the nominated conditions, including sarcopenia, obesity and hip-fracture recovery. It highlighted small samples, short studies and missing or unproven clinically meaningful improvements. That assessment is not a trial of trained young adults, nor a prediction that every individual will respond identically. It does mean that a hormone increase alone is an inadequate basis for promising useful muscle or recovery results. FDA evaluation, conclusions
A study description also does not provide a validated personal dosing schedule. Neither an online before-and-after photograph nor an increased IGF-1 result supplies the missing controlled evidence.
Ibutamoren is not FDA-approved. FDA's consumer warning lists fluid retention, altered glucose metabolism and insulin sensitivity, fatigue, muscle pain and possible heart-failure risk in some people. Long-term effects remain uncertain. FDA safety notice
The 2024 review also describes a hip-fracture trial stopped early after a congestive-heart-failure safety signal. Those patients differ from healthy lifters; the finding should neither be dismissed nor converted into a personal risk percentage. Research monitoring is not proof that self-directed use is safe. FDA safety review
If you are comparing a claim with a paper, match the actual population, product, duration and measured outcome. A matching ingredient name does not establish that a vendor's capsule or solution is equivalent to the trial material.
The MK-677 reference page connects to existing supplier listings. Those listings include affiliate links, from which Biomogging may earn a commission. Their presence is not evidence of product quality, clinical equivalence or suitability for human use. Use the human-evidence checklist to examine the claim before treating a reported laboratory or scan change as a promised physique result.
Powered by BTST